PMS, PMDD and cannabis: could endocannabinoid signaling be involved?

PMS and PMDD are related but not the same

Premenstrual syndrome (PMS) may include bloating, breast tenderness, fatigue, headaches, irritability and changes in appetite. Premenstrual dysphoric disorder (PMDD) is a more severe, cyclical disorder in which symptoms such as depressed mood, anxiety, anger, a sense of losing control or difficulty concentrating can substantially disrupt life. PMDD is not simply a matter of unusually high hormone concentrations. Research points instead to altered sensitivity to normal hormonal changes in vulnerable individuals.

Hormones, the brain and allopregnanolone

Progesterone is metabolized into allopregnanolone, a neuroactive steroid that modulates GABA-A receptors. Differences in responses to this changing signal are part of current biological models of PMDD. Serotonin, stress circuits and the endocannabinoid system may interact with these pathways. This remains an active field of study, and a biological connection should not be converted into a claim that any particular cannabinoid treats PMDD.

Anandamide can vary over the menstrual cycle

Human research has reported changes in circulating anandamide, a naturally produced endocannabinoid, across menstrual phases, with relatively high concentrations around ovulation and lower concentrations in the late luteal phase. The late luteal phase is when many premenstrual symptoms arise. The timing is intriguing, but it does not show that low anandamide causes PMDD. There is no validated blood-anandamide test that diagnoses PMDD, and the disorder should not be described as a proven cannabinoid deficiency.

A 2026 survey: common use, uncertain benefit

A survey published in 2026 received 703 responses; its menstrual-cycle analysis included 634 people who had menstruated within the preceding year. Of these, 167 met the study's definition of a history of clinician-diagnosed PMDD, based on daily symptom tracking over two cycles. Cannabis was the most commonly reported substance used to manage premenstrual mood symptoms: 30.0% overall and 51.5% in the PMDD group. Respondents reported greater use in the luteal than in the follicular phase, and more severe symptoms were associated with more frequent use. These are notable descriptions of behavior, not estimates of treatment effectiveness.

The direction of cause and effect matters

A person may use more cannabis precisely when symptoms worsen. In an observational study, higher symptom scores and higher cannabis use can therefore appear together even if cannabis helps, does nothing or worsens some symptoms. Self-selection, recall and coping motives complicate interpretation. To demonstrate a real therapeutic benefit, researchers would need controlled trials with validated mood and physical outcomes, consistent formulations and measurements across well-defined menstrual phases.

THC and CBD may affect mood differently

Some users report short-term relaxation or easier sleep with THC. Others experience anxiety, agitation, poor concentration, dysphoria or paranoia, especially with certain doses or personal vulnerabilities. CBD has been researched in other anxiety-related settings, but those studies are not trials of PMDD; an effect in one condition cannot simply be transferred to another. Neither THC nor CBD has established clinical efficacy as a PMDD treatment on the evidence discussed here.

Diagnosis and proven care should remain central

Prospective daily symptom ratings over at least two menstrual cycles help demonstrate a consistent pattern, rather than relying on a general recollection of feeling worse before menstruation. A clinician can also evaluate depression, anxiety, medication effects and other conditions. Established care may involve cognitive-behavioral approaches, selected antidepressants or hormonal options depending on individual circumstances. Cannabis use should be discussed honestly without replacing that evaluation or treatment.

Dependence and future research questions

Relief-seeking during a recurring difficult time may gradually become frequent use outside that window. Monitoring sleep, mood, function and reliance on cannabis is therefore important. Future studies should test whether the same cannabinoid has different effects at different cycle phases, and should separate cramps or sleep problems from core PMDD mood symptoms. Until controlled evidence exists, the correct conclusion is that cannabis self-use is common among some people with PMS or PMDD, but its effectiveness and safety for these disorders remain unproven.

Original references and Hebrew article

This article is an editorial adaptation of the Hebrew original.

1. Nazareth M, et al. Cannabis, Psychedelics, and Other Substance Use to Manage Premenstrual Symptoms: A Survey Study. 2026. Find publication ↗
2. Joyce KM, et al. The impact of depressed mood and coping motives on cannabis use quantity across the menstrual cycle in those with and without PMDD. Addiction. 2021. Find publication ↗
3. El-Talatini MR, Taylor AH, Konje JC. The relationship between plasma levels of the endocannabinoid, anandamide, sex steroids, and gonadotrophins during the menstrual cycle. Fertility and Sterility. 2010;93(6):1989–1996. Read the publication ↗
4. 2026 survey of substance use for premenstrual symptoms Find publication ↗

Read original Hebrew article ↗

Educational information only. This page is not a diagnosis or a treatment recommendation. Do not alter prescribed care without consulting the treating clinician, especially in neurological illness, fertility planning or pregnancy.